These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11455828)

  • 21. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.
    Björk T; Piironen T; Pettersson K; Lövgren T; Stenman UH; Oesterling JE; Abrahamsson PA; Lilja H
    Urology; 1996 Dec; 48(6):882-8. PubMed ID: 8973671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
    Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
    Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study.
    Kuriyama M; Ueno K; Uno H; Kawada Y; Akimoto S; Noda M; Nasu Y; Tsushima T; Ohmori H; Sakai H; Saito Y; Meguro N; Usami M; Kotake T; Suzuki Y; Arai Y; Shimazaki J
    Int J Urol; 1998 Jan; 5(1):48-54. PubMed ID: 9535601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Usefulness of the percentage of free prostatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer].
    Gaspar MJ; Arribas I; Hontoria JM; Bokobo P; Coca C; Angulo JC
    Med Clin (Barc); 2000 Sep; 115(9):332-6. PubMed ID: 11093893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical utility of the free prostate specific antigen (PSA), alpha 1-antichymotrypsin-complexed PSA, and free/total PSA ratio using the specific and sensitive enzyme-linked immunosorbent assay "E-plate EIKEN PSA"].
    Imai K; Yamanaka H; Kubota Y; Miki M; Ito T; Akaza H; Uchida K; Egawa S; Kuriyama M; Watanabe H; Okihara K; Kotake T; Usami M; Arai Y; Maeda H; Sagiyama K; Saito Y; Sakai H; Shida K
    Hinyokika Kiyo; 1998 Oct; 44(10):755-63. PubMed ID: 9850846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
    BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer].
    de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I
    Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
    Christensson A; Björk T; Nilsson O; Dahlén U; Matikainen MT; Cockett AT; Abrahamsson PA; Lilja H
    J Urol; 1993 Jul; 150(1):100-5. PubMed ID: 7685416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Factors affecting the PSA:alpha 1 antichymotrypsin/total PSA ratio].
    Martínez Sarmiento M; España F; Royo M; Estellés A; Aznar J; Peinado F; Alapont JM; Vera Donoso CD; Jiménez Cruz JF
    Actas Urol Esp; 2001 May; 25(5):350-6. PubMed ID: 11512259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia.
    España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
    Eur Urol; 1997; 32(3):268-72. PubMed ID: 9358211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.
    Okihara K; Cheli CD; Partin AW; Fritche HA; Chan DW; Sokoll LJ; Brawer MK; Schwartz MK; Vessella RL; Loughlin KR; Johnston DA; Babaian RJ
    J Urol; 2002 May; 167(5):2017-23; discussion 2023-4. PubMed ID: 11956430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the extent of prostate cancer using a combination of serum prostate-specific antigen-alpha(1)-antichymotrypsin complex and systematic biopsy.
    Miyake H; Hara S; Yamanaka N; Ono Y; Eto H; Yamada Y; Takechi Y; Arakawa S; Kamidono S; Hara I
    Urol Int; 2002; 68(4):232-6. PubMed ID: 12053023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
    Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
    Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study of free to total prostate specific antigen ratio in the detection of patients with prostate cancer].
    Ohuchi H; Mikata K; Miyoshi Y; Ohta J; Osada Y; Uemura H; Yao M; Takeda M; Noguchi S; Kubota Y; Hosaka M; Jinza S; Asakura T; Ebato T
    Nihon Hinyokika Gakkai Zasshi; 2000 Dec; 91(12):695-9. PubMed ID: 11201129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate.
    Kobayashi T; Kamoto T; Isogawa Y; Kinoshita H; Terai A; Habuchi T; Ogawa O
    J Urol; 2003 Jan; 169(1):121-4. PubMed ID: 12478118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.